DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
? Autolus Therapeutics
NASDAQ: AUTL
Report Analisi Approfondita | AUCATZYL obe-cel • CD19 CAR-T • B-ALL FDA Approved • Lupus Nephritis Phase 1 • MS Pipeline
Current Price
$1.41
Analyst Target
$9.12
Upside Potential
+545%
Market Cap
$375M
? Andamento Prezzo 6 Mesi (Maggio – Novembre 2025)
Prezzo Massimo
$4.12
Prezzo Minimo
$1.11
Range 6M
$3.01 (271%)
Volatilità
ULTRA ALTA
? Executive Summary
Autolus Therapeutics è una biotech commerciale specializzata in CAR-T cell therapy. Il suo principale asset AUCATZYL (obe-cel) è il primo CD19 CAR-T therapy approvato negli USA, UK e EU per B-ALL relapsed/refractory, con straordinario potenziale di espansione in lupus nephritis e multiple sclerosis.
? CATALIZZATORE IMMINENTE – DOMANI:
- Novembre 12, 2025 (DOMANI @ 8:30 AM EST): Q3 2025 Earnings Report LIVE + Conference Call
- Late 2025: Full data lupus nephritis Phase 1 CARLYSLE trial (3 pazienti con complete renal response)
- Year-End 2025: Prima dose MS Phase 1 (first patient dosing progressive multiple sclerosis)
- Phase 2 Lupus: Pivotal trial initiato by year-end 2025
Profilo Aziendale
- Market Cap: $375 milioni (micro-cap growth)
- Cash Position: $454.3M (June 30, 2025) – Molto forte
- Lead Product: AUCATZYL (obe-cel) – CD19 CAR-T, FDA-approved B-ALL
- Revenue TTM: $30.18M – Stage commerciale iniziale
- Focus Terapeutico: CAR-T oncology + expansion in autoimmune (lupus, MS)
AUCATZYL: Franchise Multi-Indicazione
- B-ALL Approved (USA/UK/EU): Commerciale, 60 centri USA entro fine 2025
- Lupus Nephritis Phase 1: 3 pazienti con complete renal response a month 3 – PROMETTENTE
- Progressive MS Phase 1: First patient dosing atteso year-end 2025
- Dual CD19/CD22 Targeting: AUTO6 candidate per escape prevention
⚡ Catalizzatori Dettaglio & Timeline
1. Q3 2025 Earnings – DOMANI (Nov 12 @ 8:30 AM EST)
CATALIZZATORE IMMEDIATO. Autolus riporterà Q3 2025 risultati finanziari + commercial update AUCATZYL uptake.
- Q2 2025 Revenue: $20.9M (incremento sequenziale da Q1 $9M)
- H1 2025 Total: $29.9M (tracking towards $80-120M run-rate)
- Expected Topics: B-ALL uptake trajectory, lupus data, MS initiation timing
- Market Impact: Beat estimates potrebbe triggare +10-20% move
2. Lupus Nephritis Phase 1 Data – H2 2025
BREAKTHROUGH POTENTIAL. CARLYSLE trial mostra 3/3 pazienti con complete renal response.
- Current Data: 3 SLE pazienti, complete renal response at month 3 – STRAORDINARIO
- Full Data Timing: H2 2025 medical conference presentation
- Phase 2 Pivotal: Enrollment partirà year-end 2025
- Market Opportunity: Lupus nephritis è indicazione grave con unmet need $5B+ TAM
- Stock Impact: Se dati rimangono positive, +50-100% move possibile
3. Progressive MS Phase 1 – Year-End 2025
MS EXPANSION. First patient dosing atteso entro fine 2025.
- Indication: Progressive multiple sclerosis – unmet need, large market $8-10B+ TAM
- Mechanism: B-cell depletion via CD19 CAR-T – validated in autoimmunity
- Competitive Advantage: Autolus è SOLO CAR-T in development per autoimmune
? Financial Position & Sustainability
Fortress Balance Sheet
- Cash & Equivalents: $454.3M (June 30, 2025)
- No Debt: Clean balance sheet
- Burn Rate: ~$60-80M per quarter (R&D + commercial)
- Cash Runway: 2+ years fully funded without revenue
Revenue Trajectory
- Q1 2025: $9.0M (AUCATZYL commercial launch)
- Q2 2025: $20.9M (+132% sequential) – Acceleration
- Q3 2025: Expected $20-25M (seasonal patterns)
- 2025 Full-Year: $70-80M potential (first full commercial year)
- Peak Sales B-ALL Alone: $200-300M+ (as market penetrates)
Upside Scenarios
- Lupus Approval: +$400-600M peak sales opportunity
- MS Success: +$1-2B peak sales (larger market)
- Multi-Indication: Total CAR-T franchise could reach $2-3B+ peak sales
⚠️ Risk & Opportunity
? Downside Risks
- Q3 Earnings Miss: Se revenue guidance delude
- B-ALL Uptake Slow: Commercial execution challenges
- Lupus Data Setback: Se Phase 1 results deludono
- MS Safety: If Phase 1 shows safety issues
- Dilution Risk: Potrebbe necesario capital raise
? Upside Opportunities
- Q3 Beat Tomorrow: +10-20% move if upside surprise
- Lupus Phase 2 Launch: Potential blockbuster indication
- MS Phase 1 Success: +50-100% move potential per patient dosing
- Multi-Indication Franchise: $2-3B peak sales TAM
- M&A Target: Big pharma acquisition interest at $5-10/share
- Analyst Upgrades: Currently Strong Buy @ $9.12 target
? Valuation Scenarios & Price Targets
Bull Case (Multi-Indication Success)
Analyst Target (12M)
$9.12
+545% upside
Bull Case (2026)
$12-15
+750% to +960%
Base Case
$5-7
+254% to +396%
Bear Case (Both Catalysts Failure)
Bear Case
$0.80-1.00
-43% to -29% downside
? Trading Strategy “Catalyst Run-Up”
Two Major Catalysts – ULTRA HIGH VOLATILITY
Setup Ideale Micro-Cap Biotech:
- ✅ Catalyst DOMANI (Q3 earnings)
- ✅ Analyst target $9.12 vs current $1.41 = 545% upside
- ✅ Multiple value inflection points (earnings, lupus data, MS initiation)
- ✅ Strong cash position elimina dilution risk short-term
- ✅ Micro-cap = 100%+ moves not-rare su positive catalysts
Entry Strategy
- Pre-Earnings Zone: $1.30-1.50 (accumulation)
- If Earnings Beat: Breakout to $1.80-2.00+
- Lupus Data Phase 2 Initiation: Target $5-7 medium-term
- MS Initiation Year-End: Potential $7-10 target
✅ Investment Recommendation
Rating: STRONG BUY – ULTRA VOLATILE
Key Reasons
- Earnings Tomorrow: Immediate catalyst 8:30 AM EST
- Multi-Catalyst Setup: Earnings + lupus + MS = 3 shots 2025-2026
- 545% Upside: Analyst target $9.12 (Strong Buy consensus)
- Fortress Balance: $454M cash, no debt
- Breakthrough Therapy: AUCATZYL in lupus – unmet need indication
- Micro-Cap Volatility: +100%+ moves realistic per catalyst
Price Targets
- Immediate (Post-Earnings): $1.80-2.20 (+27-56%)
- 6-Month (Lupus Phase 2): $5-7 (+254-396%)
- 12-Month (MS + multi-indication): $9-12+ (+545-750%)
⏰ Earnings Call DOMANI – 12 Nov 2025 @ 8:30 AM EST
Segui LIVE Autolus Q3 earnings announcement + conference call
Accedi Investor Relations →? Autolus Therapeutics
NASDAQ: AUTL
Complete Analysis Report | AUCATZYL obe-cel • CD19 CAR-T • B-ALL FDA Approved • Lupus Nephritis Phase 1 • MS Pipeline
Current Price
$1.41
Analyst Target
$9.12
Upside Potential
+545%
Market Cap
$375M
? Price Performance 6 Months (May – November 2025)
Peak Price
$4.12
Lowest Price
$1.11
6M Range
$3.01 (271%)
Volatility
ULTRA HIGH
? Executive Summary
Autolus Therapeutics is a commercial-stage biotech specializing in CAR-T cell therapy. Its lead asset AUCATZYL (obe-cel) is the first CD19 CAR-T therapy approved in USA, UK, and EU for relapsed/refractory B-ALL, with extraordinary potential for expansion into lupus nephritis and multiple sclerosis.
? IMMEDIATE CATALYST – TOMORROW:
- November 12, 2025 (TOMORROW @ 8:30 AM EST): Q3 2025 Earnings Report LIVE + Conference Call
- H2 2025: Full data lupus nephritis Phase 1 CARLYSLE trial
- Year-End 2025: First patient dosing MS Phase 1
- Phase 2 Lupus: Pivotal trial initiation expected by year-end
Company Profile
- Market Cap: $375 million (micro-cap biotech)
- Cash Position: $454.3M (June 30, 2025) – Very strong
- Lead Product: AUCATZYL (obe-cel) – CD19 CAR-T, FDA-approved B-ALL
- Revenue TTM: $30.18M – Early commercial stage
- Focus: CAR-T oncology + autoimmune expansion (lupus, MS)
AUCATZYL: Multi-Indication Franchise
- B-ALL Approved (USA/UK/EU): Commercial, 60 US centers by end 2025
- Lupus Nephritis Phase 1: 3 patients with complete renal response at month 3 – PROMISING
- Progressive MS Phase 1: First patient dosing expected year-end 2025
- Dual CD19/CD22 Targeting: AUTO6 candidate for escape prevention
⚡ Catalysts Detail & Timeline
1. Q3 2025 Earnings – TOMORROW (Nov 12 @ 8:30 AM EST)
IMMEDIATE CATALYST. Autolus will report Q3 2025 financial results + AUCATZYL commercial update.
- Q2 2025 Revenue: $20.9M (sequential increase from Q1 $9M)
- H1 2025 Total: $29.9M (tracking towards $80-120M run-rate)
- Expected Topics: B-ALL uptake trajectory, lupus data, MS initiation timing
- Market Impact: Beat estimates could trigger +10-20% move
2. Lupus Nephritis Phase 1 Data – H2 2025
BREAKTHROUGH POTENTIAL. CARLYSLE trial shows 3/3 patients with complete renal response.
- Current Data: 3 SLE patients, complete renal response at month 3 – EXTRAORDINARY
- Full Data Timing: H2 2025 medical conference presentation
- Phase 2 Pivotal: Enrollment to start year-end 2025
- Market Opportunity: Lupus nephritis is severe indication with $5B+ unmet need TAM
- Stock Impact: If data remains positive, +50-100% move possible
3. Progressive MS Phase 1 – Year-End 2025
MS EXPANSION. First patient dosing expected by year-end.
- Indication: Progressive multiple sclerosis – $8-10B+ TAM
- Mechanism: B-cell depletion via CD19 CAR-T – validated in autoimmunity
- Competitive Advantage: Autolus ONLY CAR-T in development for autoimmune
? Financial Position & Sustainability
Fortress Balance Sheet
- Cash & Equivalents: $454.3M (June 30, 2025)
- No Debt: Clean balance sheet
- Burn Rate: ~$60-80M per quarter (R&D + commercial)
- Cash Runway: 2+ years fully funded
Revenue Trajectory
- Q1 2025: $9.0M (AUCATZYL commercial launch)
- Q2 2025: $20.9M (+132% sequential)
- 2025 Full-Year: $70-80M potential
- Peak Sales B-ALL: $200-300M+ opportunity
Multi-Indication Upside
- Lupus Approval: +$400-600M peak sales
- MS Success: +$1-2B peak sales
- Total CAR-T Franchise: $2-3B+ peak sales potential
⚠️ Risk & Opportunity
? Downside Risks
- Q3 Earnings Miss: If revenue disappoints
- B-ALL Slow Uptake: Commercial execution challenges
- Lupus Data Setback: If Phase 1 results disappoint
- MS Safety Issues: If Phase 1 shows safety concerns
- Dilution Risk: Potential capital raise needed
? Upside Opportunities
- Q3 Beat Tomorrow: +10-20% move if upside surprise
- Lupus Phase 2 Launch: Potential blockbuster indication
- MS Phase 1 Success: +50-100% move potential
- Multi-Indication Franchise: $2-3B peak sales
- M&A Target: Big pharma acquisition at $5-10/share
- Analyst Upgrades: Strong Buy @ $9.12 target
? Valuation Scenarios
Bull Case (Multi-Indication Success)
Analyst Target (12M)
$9.12
+545% upside
Bull Case (2026)
$12-15
+750% to +960%
Base Case
$5-7
+254% to +396%
Bear Case
Bear Case
$0.80-1.00
-43% to -29% downside
? Trading Strategy
Micro-Cap Biotech Setup – ULTRA HIGH VOLATILITY:
- ✅ Catalyst TOMORROW (Q3 earnings)
- ✅ Analyst target $9.12 vs current $1.41 = 545% upside
- ✅ Multiple value inflection points (earnings, lupus, MS)
- ✅ Strong cash eliminates dilution risk near-term
- ✅ Micro-cap = 100%+ moves common on positive catalysts
Entry Strategy
- Pre-Earnings Zone: $1.30-1.50
- If Earnings Beat: Breakout to $1.80-2.00+
- Lupus Phase 2 Initiation: Target $5-7
- MS Initiation Year-End: Target $7-10
✅ Investment Recommendation
Rating: STRONG BUY – ULTRA VOLATILE
Key Reasons
- Earnings Tomorrow: Immediate catalyst
- Multi-Catalyst Setup: Earnings + lupus + MS
- 545% Upside: Analyst target $9.12
- Fortress Balance: $454M cash, no debt
- Breakthrough Therapy: AUCATZYL in lupus
- Micro-Cap Volatility: 100%+ moves realistic
Price Targets
- Immediate (Post-Earnings): $1.80-2.20 (+27-56%)
- 6-Month (Lupus Phase 2): $5-7 (+254-396%)
- 12-Month (MS + multi-indication): $9-12+ (+545-750%)
⏰ Earnings Call TOMORROW – 12 Nov 2025 @ 8:30 AM EST
Follow LIVE Autolus Q3 earnings announcement + conference call
Access Investor Relations →Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
